Navigation Links
New research to reduce drug side-effects
Date:7/10/2009

They are a group of drugs which millions of people rely on to keep pain at bay but they can have unwanted side-effects which are sometimes more serious than the original health problem. Now scientists at The University of Nottingham are taking part in the largest-ever study on the safety of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) that has ever been performed.

The project is called SOS (Safety Of non-Steroidal anti-inflammatory drugs) and will study the medical information of 35 million people in Europe to assess the incidence and nature of harmful side-effects on the cardiovascular and gastrointestinal systems of patients. It's hoped the results will lead to better guidance for doctors on how to balance the advantages of prescribing the drugs with the associated risks of heart and digestive problems.

NSAIDS are widely used in medicine for treating pain, inflammation and degenerative diseases like arthritis. The most commonly-used are aspirin and ibuprofen. But their use is associated with an increased risk of minor and serious gastrointestinal complications. It's estimated that there are thousands of these cases in the European Union every year. Prompted by these problems, a new class of NSAIDS called 'Coxibs' have been developed to reduce the risk of this type of side-effect, but the use of these new drugs has since been linked with an increased risk of heart problems such as heart attack and stroke.

Clinicians and scientists now agree that the risk of stomach problems has to be balanced against the risk of cardiovascular interference. Both risks may differ in one person and for the 30 different types of NSAIDS available in the EU. Up to now research studies have been too small to be effective in terms of providing decision models for doctors and drug regulators but it's hoped this new large survey will result in a much more accurate prescription method to minimize drug-related harm.

Over the next two and a half years, published literature on previous clinical trials and observational studies will be scrutinized to identify any methodological inconsistencies and knowledge gaps and this information will be used to design and carry out an EU-wide observational study. This study will be the biggest of its kind ever undertaken in this field. It will include data from more than 35 million Europeans, taken from existing healthcare databases in the UK, the Netherlands, Germany and Italy. The researchers will use the data to create a variety of decision models to help doctors prescribe the most suitable type of NSAID for a particular patient and lower the risk of unwanted gastrointestinal or cardiovascular side-effects.

The University of Nottingham is working with ten other leading European research institutions on the three-year project which is being funded with a 2.8 million Euros grant from the EC's 7th Framework Programme. Fundamental to the project is QResearch, a not-for-profit partnership between The University of Nottingham and leading primary care system supplier EMIS, which uses data collected over the past 17 years.

Professor of Clinical Epidemiology and General Practice, Julia Hippisley-Cox, who founded QResearch, said: "The SOS project will help quantify and compare the risks of different NSAIDs based on an individual's profile and should help lead patients and doctors make better decisions regarding treatment options".


'/>"/>

Contact: Professor Julia Hippisley-Cox
julia.h-cox@nottingham.ac.uk
44-011-584-66915
University of Nottingham
Source:Eurekalert

Related medicine news :

1. Pre-cessation patch doubles quit success rate: Researchers call for labeling changes
2. Conning Research: Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011
3. Velos, Inc. Launches Velos On-Demand for Velos eResearch, Bringing Dynamically Scalable Economy to Customers
4. 'Comparative Effectiveness' Research Addresses Options for Treating Prostate Cancer
5. Lupus Foundation of America Accepting Letters of Intent for Research Grants on Adult Stem Cell Research and Health-Related Quality of Life in Pediatric Lupus
6. Researchers identify potential patient safety risks among methadone maintenance treatment patients
7. Photos: $8 Million in Asthma Research Grants Awarded to 12 Scientists
8. Kessler Foundation Research Center Awarded More Than Two Million Dollars in Grants
9. Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research
10. DOE funds Clemson University clean energy research
11. UT Southwestern researcher named HHMI Early Career Physician-Scientist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... 28, 2017 , ... At its first ginger symposium on July 18, 2017, ... industry. The funds will be used for land preparation, seed and organic farming for ... will support both new and existing small-hold farmers and will also help strengthen the ...
(Date:7/28/2017)... ... July 28, 2017 , ... Kevin Harrington, one of the original Sharks from hit reality series ... a new DRTV campaign with My Real Earth. , Most people put their healthcare above ... as important as what we put in our bodies. After all, the skin is the ...
(Date:7/28/2017)... , ... July 28, 2017 , ... The DuPage County ... hiring of associate Jennifer M. Cusack. Ms. Cusack joins the team ready ... Ms. Cusack graduated from Bradley University in Peoria, Illinois, with a BA in ...
(Date:7/28/2017)... ... 28, 2017 , ... Join Becker's Healthcare as they host their 3rd Annual ... IL. Great sessions on Epic, Cyber Security, Telehealth, Mobile Health, Revenue Cycle Optimization, Predictive ... George W. Bush, 43rd President of the United States ...
(Date:7/28/2017)... ... July 28, 2017 , ... Lundquist Insurance ... to business owners and families across east Texas, is embarking on a charity ... the greater Dallas area. , America’s Mighty Warriors offers a series of programs ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... -- The Galien Foundation announced today the 2017 ... Award Nominees. Counted among the global health innovation industry,s ... and technology product achievement that improves the human condition. ... must be U.S. Food and Drug Administration (FDA) approved for ... to impact human health. Sales data are not considered by ...
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
Breaking Medicine Technology: